Rein Therapeutics
Price & Volume
Stats
See more52W Range | $1.04-$3.50 |
Market Cap | $32.5M |
Shares Short | 420,743 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.94 |
News
See moreYahoo Finance • 2 months ago
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Yahoo Finance • 3 months ago
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Yahoo Finance • 3 months ago
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
Yahoo Finance • 4 months ago
Rein Therapeutics files to sell 10M shares of common stock for holders
About
CEO | Dr. James Brian Windsor Ph.D. |
CFO | Mr. Timothy M. Cunningham CPA, M.B.A. |
Address | 12407 N. Mopac Expy., Austin, TX, United States, 78758 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 11 |
